Clearly, in almost all of the other cases, GM-CSF was utilized and two published cases reported no significant response when GM-CSF was used as monotherapy [6,8]. GM-CSF, which plays a crucial role in the production and activation of white blood cells, holds promise in various clinical contexts, but its effectiveness as a single treatment modality may not be enough to cause considerable improvement for immunotherapy-related neutropenia. This evidence concerns the gene CSF2 and neutropenia.